Lung and liver changes during COVID-19 infection in the presence of liver cirrhosis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Patients with severe fibrosis and cirrhosis of the liver are a vulnerable group that is at an increased risk for infection with COVID-19 and hads its severe course due to the development of a systemic immunodeficiency state. The paper describes a case of severe COVID-19 infection associated with liver cirrhosis (Child-Pugh class B) in a 52-year-old female patient with a fatal outcome. The main causes of death were respiratory complications, as well as sudden deterioration in liver function, which led to end-stage disease.

Full Text

Restricted Access

About the authors

Olga V. Vorobyeva

I.N. Ulyanov Chuvash State University

Email: olavorobeva@mail.ru
Cand. Med. Sci., Associate Professor, Department of General and Clinical Morphology and Forensic Medicine Cheboksary, Russia

Aleksey V. Lastochkin

I.N. Ulyanov Chuvash State University; Republican Bureau of Forensic Medicine

Email: alllex.08@mail.ru
Highest-Category Pathologist Cheboksary, Russia; Cheboksary, Russia

Natalia E. Gimaldinova

I.N. Ulyanov Chuvash State University

Email: rufer06@rambler.ru
Cand. Med. Sci., Associate Professor, Department of General and Clinical Morphology and Forensic Medicine Cheboksary, Russia

Lyubov P. Romanova

I.N. Ulyanov Chuvash State University

Email: samung2008@yandex.ru
Associate Professor, Department of Dermatovenereology with Course of Hygiene Cheboksary, Russia

Aleksandr A. Yusov

I.N. Ulyanov Chuvash State University

Email: yusov1961@yandexl.ru
Associate Professor, Department of Normal and Pathological Physiology Cheboksary, Russia

References

  1. Воробьева О.В., Ласточкин А.В. Клиникоморфологический случай COVID-19. Эпидемиол. инфекц. болезни. Актуал. вопр. 2020; 10(2): 90-3. DOI: https://dx.doi.org/10.18565/epidem.2020.2.90-93
  2. Воробьева О.В., Ласточкин А.В. Патоморфологические изменения в органах при COVID-19. Инфекция и иммунитет 2020; 10(3): 587-90. https://doi.org/10.15789/2220-7619-PCI-1483
  3. Chai X., Hu L., Zhang Y., Han W., Lu Z., Ke A. et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. bioRxiv. doi: 10.1101/2020.02.03.931766
  4. Fan Z., Chen L., Li J., Cheng X., Yang J., Tian C. et al. Clinical features of COVID-19 related liver damage. Clin. Gastroenterol. Hepatol. 2020; 18(7): 1561-6. doi: 10.1016/j. cgh.2020.04.002
  5. Hamming I., Timens W., Bulthuis M., Lely A.T., Navis G.J., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004; 203: 631-7.
  6. Li L., Li S., Xu M., Yu P., Zheng S., Dua Z. et al. Risk factors related to hepatic injury in patients with corona virus disease 2019. medRxiv 2020. doi: https://doi.org/10.1101/2020.02.28.20028514.
  7. Moon A.J. et al. High mortality rate for SARS-CoV2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry. J. Hepatol. (advance online publication), 22 May 2020. https://doi.org/10.1016/johep.2020.05.013
  8. Sun J., Aghemo A., Forner A., Valenti L. COVID-19 and liver disease. Liver Int. 2020; 40(6): 1278-81. https://doi.org/10.1111/liv.14470

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media